# ADVANCES IN Immunology

EDITED BY

FRANK J. DIXON

VOLUME 38

1986

58.6919.1 121.1 138

# ADVANCES IN Immunology

**EDITED BY** 

FRANK J. DIXON

Scripps Clinic and Research Foundation La Jolla, California

ACADEMIC PRESS, INC.

Harcourt Brace Jovanovich, Publishers Orlando San Diego New York Austin London Montreal Sydney Tokyo Toronto COPYRIGHT © 1986 BY ACADEMIC PRESS, INC.
ALL RIGHTS RESERVED.
NO PART OF THIS PUBLICATION MAY BE REPRODUCED OR
TRANSMITTED IN ANY FORM OR BY ANY MEANS, ELECTRONIC
OR MECHANICAL, INCLUDING PHOTOCOPY, RECORDING, OR
ANY INFORMATION STORAGE AND RETRIEVAL SYSTEM, WITHOUT
PERMISSION IN WRITING FROM THE PUBLISHER.

ACADEMIC PRESS, INC. Orlando, Florida 32887

United Kingdom Edition published by ACADEMIC PRESS INC. (LONDON) LTD. 24-28 Oval Road, London NW1 7DX

LIBRARY OF CONGRESS CATALOG CARD NUMBER: 61-17057

ISBN 0-12-022438-0

PRINTED IN THE UNITED STATES OF AMERICA

86 87 88 89 9 8 7 6 5 4 3 2 1

# **CONTRIBUTORS**

- Numbers in parentheses indicate the pages on which the authors' contributions begin.
- R. D. Campbell (203), MRC Immunochemistry Unit, Biochemistry Department, Oxford, England
- M. C. CARROLL (203), Department of Pediatrics, Children's Hospital Medical Center, Harvard Medical School, Boston, Massachusetts 02115
- DENNIS A. CARSON (275), Department of Basic and Clinical Research, Scripps Clinic and Research Foundation, La Jolla, California 92037
- CARLO M. CROCE (245), The Wistar Institute of Anatomy and Biology, Philadelphia, Pennsylvania 19104
- JOYCE K. CZOF (361), Department of Rheumatology and Immunology, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts 02115
- BRUCE D. FREIMARK (275), Department of Basic and Clinical Research, Scripps Clinic and Research Foundation, La Jolla, California 92037
- MARILYN M. HUSTON (313), Department of Microbiology and Immunology, Howard Hughes Medical Institute Laboratory, Baylor College of Medicine, Houston, Texas 77030
- JOHN KAPPLER (1), Department of Medicine, National Jewish Hospital and Research Center, and Departments of Biophysics, Biochemistry and Genetics, Departments of Microbiology, and Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado 80262
- PHILIPPA MARRACK (1), Department of Medicine, National Jewish Hospital and Research Center, and Departments of Biophysics, Biochemistry and Genetics, Departments of Microbiology, and Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado 80262
- Peter C Nowell (245), Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104
- R. R. PORTER (203), MRC Immunochemistry Unit, Biochemistry Department, Oxford, England
- ROBERT R. RICH (313), Department of Microbiology and Immunology,

- Howard Hughes Medical Institute Laboratory, Baylor College of Medicine, Houston, Texas 77030
- JOHN R. RODGERS (313), Department of Microbiology and Immunology, Howard Hughes Medical Institute Laboratory, Baylor College of Medicine. Houston. Texas 77030
- RONALD H. SCHWARTZ (31), Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maruland 20205
- ROGER SMITH III<sup>1</sup> (313), Department of Microbiology and Immunology, Howard Hughes Medical Institute Laboratory, Baylor College of Medicine, Houston, Texas 77030

<sup>&</sup>lt;sup>1</sup>Present address: Department of Veterinary Pathology, Texas A & M University, College Station, Texas 77843.

# CONTENTS

Conte	RIBUTORS	ix
The An	tigen-Specific, Major Histocompatibility Complex-Restricted Receptor on T Cells	
	PHILIPPA MARRACK AND JOHN KAPPLER	
I.	Introduction	ì
II.	Identification and Properties of T Cell Receptor Proteins	3
III.	Properties of cDNA and Genomic Clones Encoding T Cell Receptor Proteins	5
IV.	Other Receptor-Like Genes in T Cells	· 10
V.	Rearrangement and Expression of T Cell Receptor Genes in the Thymus	10
VI.	Expression of Receptor Genes and Proteins on Peripheral T Cells	13
VII.	V Region Repertoire and Variability	15
VIII.	Chromosomal Mapping of T Cell Receptor Genes	16
IX.	Allelic Exclusion of T Cell Receptor Genes	17
Χ.	Association of the Receptor and T3	18
XI.	Is the Receptor Responsible for Specific Binding to Both Antigen and MHC	. 10
	by T Cells?	19
XII.	Interactions of T Cells with Their Targets	1:21
XIII.	Concluding Remarks	23 24
	References	24
İmmun	e Response (Ir) Genes of the Murine Major Histocompatibility Complex	
	RONALD H. SCHWARTZ	,
I.	Introduction	31
II.	Early Observations	33
III.	Cellular Sites of Expression of Ir Genes	50
IV.	Parallels between MHC Restriction and Ir Gene Control	63
	Ia Molecules Are the Ir Gene Products	67
	Theories of Ir Gene Function	91
	Ir Gene Control of T Cell-T Cell Interactions	153
VIII.	Ir Gene Control of Cytotoxic T Cell Responses	161
IX.	Conclusion	188
	References	190
The M	tolecular Genetics of Components of Complement	-
1110 19	R. D. CAMPBELL, M. C. CARROLL, AND R. R. PORTER	
	N. D. CAMPBELL, M. C. CARROLL, AND R. R. FORTER	٠ د
T	Introduction	203
	C2 and Factor B	207
	. C4	219
111.	· • • • • • • • • • • • • • • • • • • •	

v

# CONTENTS

V. C3 VI. C5 VII. C9	2
	-
	2
VIII. C4b-Binding Protein (C4bp)	
IX. Summary	_
References	-
References	
Molecular Genetics of Human B Cell Neoplasia	
CARLO M. CROCE AND PETER C. NOWELL	
I. Introduction	2
II. Chromosomal Translocations in B Cell Neoplasia	2
III. Translocation of the c-myc Oncogene in Burkitt Lymphomas with the t(8;14)	_
Chromosome Translocation	2
IV. Deregulation of the Translocated c-myc Oncogene in Burkitt Lymphoma	
	2
V. Molecular Genetics of the Variant Chromosome Translocations in Burkitt	
Lymphoma	
VI. Mechanisms of c-myc Activation	
VII. Molecular Genetics of the t(11;14) Chromosome Translocation	
VIII. Molecular Genetics of the t(14;18) Chromosome Translocation	2
IX Conclusions	2
References	
*	-
Human Lymphocyte Hybridomas and Monoclonal Antibodies	
DENNIS A. CABSON AND BRUCE D. FREIMARK.	
l. Introduction	. 2
II. Production of Monoclonal Antibodies by Epstein-Barr Virus-Transformed B	
Cells	. 2
III. Cell Lines for B Lymphocyte Hybridization	. 2
IV. Preparation of Donor Lymphocytes for Fusion	
IV. Preparation of Donor Lymphocytes for Fusion  V. Cell Fusion	9
IV. Preparation of Donor Lymphocytes for Fusion V. Cell Fusion VI. Human-Murine Hybridomas	. 9
IV. Preparation of Donor Lymphocytes for Fusion V. Cell Fusion VI. Human-Murine Hybridomas VII. Human-Human Hybridomas	. 2
IV. Preparation of Donor Lymphocytes for Fusion V. Cell Fusion VI. Human-Murine Hybridomas VII. Human-Human Hybridomas VIII. Human × Human-Mouse Heterohybridomas	
IV. Preparation of Donor Lymphocytes for Fusion V. Cell Fusion VI. Human-Murine Hybridomas VII. Human-Human Hybridomas VIII. Human × Human-Mouse Heterohybridomas IX. Characterization of Human Monoclonal Antibodies	
IV. Preparation of Donor Lymphocytes for Fusion  V. Cell Fusion  VI. Human-Murine Hybridomas  VII. Human-Human Hybridomas  VIII. Human × Human-Mouse Heterohybridomas  IX. Characterization of Human Monoclonal Antibodies  X. Propagation of Human-Mouse and Human-Human Hybridomas in Vivo	
IV. Preparation of Donor Lymphocytes for Fusion V. Cell Fusion VI. Human-Murine Hybridomas VII. Human-Human Hybridomas VIII. Human × Human-Mouse Heterohybridomas IX. Characterization of Human Monoclonal Antibodies X. Propagation of Human-Mouse and Human-Human Hybridomas in Vivo XI. Genetically Engineered Antibodies	
IV. Preparation of Donor Lymphocytes for Fusion V. Cell Fusion VI. Human-Murine Hybridomas VII. Human-Human Hybridomas VIII. Human × Human-Mouse Heterohybridomas IX. Characterization of Human Monoclonal Antibodies X. Propagation of Human-Mouse and Human-Human Hybridomas in Vivo XI. Genetically Engineered Antibodies	
IV. Preparation of Donor Lymphocytes for Fusion  V. Cell Fusion  VI. Human-Murine Hybridomas  VII. Human-Human Hybridomas  VIII. Human × Human-Mouse Heterohybridomas  IX. Characterization of Human Monoclonal Antibodies  X. Propagation of Human-Mouse and Human-Human Hybridomas in Vivo  XI. Genetically Engineered Antibodies  XII. Concluding Remarks	
IV. Preparation of Donor Lymphocytes for Fusion V. Cell Fusion VI. Human-Murine Hybridomas VII. Human-Human Hybridomas VIII. Human × Human-Mouse Heterohybridomas IX. Characterization of Human Monoclonal Antibodies X. Propagation of Human-Mouse and Human-Human Hybridomas in Vivo XI. Genetically Engineered Antibodies	
IV. Preparation of Donor Lymphocytes for Fusion  V. Cell Fusion  VI. Human-Murine Hybridomas  VII. Human-Human Hybridomas  VIII. Human × Human-Mouse Heterohybridomas  IX. Characterization of Human Monoclonal Antibodies  X. Propagation of Human-Mouse and Human-Human Hybridomas in Vivo  XI. Genetically Engineered Antibodies  XII. Concluding Remarks	
IV. Preparation of Donor Lymphocytes for Fusion  V. Cell Fusion  VI. Human-Murine Hybridomas  VII. Human + Human Hybridomas  VIII. Human × Human-Mouse Heterohybridomas  IX. Characterization of Human Monoclonal Antibodies  X. Propagation of Human-Mouse and Human-Human Hybridomas in Vivo  XI. Genetically Engineered Antibodies  XII. Concluding Remarks  References	
IV. Preparation of Donor Lymphocytes for Fusion  V. Cell Fusion  VI. Human-Murine Hybridomas  VII. Human-Human Hybridomas  VIII. Human × Human-Mouse Heterohybridomas  IX. Characterization of Human Monoclonal Antibodies  X. Propagation of Human-Mouse and Human-Human Hybridomas in Vivo  XI. Genetically Engineered Antibodies  XII. Concluding Remarks	
IV. Preparation of Donor Lymphocytes for Fusion  V. Cell Fusion  VI. Human-Murine Hybridomas  VII. Human-Human Hybridomas  VIII. Human × Human-Mouse Heterohybridomas  IX. Characterization of Human Monoclonal Antibodies  X. Propagation of Human-Mouse and Human-Human Hybridomas in Vivo  XI. Genetically Engineered Antibodies  XII. Concluding Remarks  References  Maternally Transmitted Antigen	
IV. Preparation of Donor Lymphocytes for Fusion  V. Cell Fusion  VI. Human-Murine Hybridomas  VII. Human + Human Hybridomas  VIII. Human × Human-Mouse Heterohybridomas  IX. Characterization of Human Monoclonal Antibodies  X. Propagation of Human-Mouse and Human-Human Hybridomas in Vivo  XI. Genetically Engineered Antibodies  XII. Concluding Remarks  References  Maternally Transmitted Antigen  JOHN R. RODGERS, ROGER SMITH III, MARILYN M. HUSTON,	
IV. Preparation of Donor Lymphocytes for Fusion  V. Cell Fusion  VI. Human-Murine Hybridomas  VII. Human-Human Hybridomas  VIII. Human × Human-Mouse Heterohybridomas  IX. Characterization of Human Monoclonal Antibodies  X. Propagation of Human-Mouse and Human-Human Hybridomas in Vivo  XI. Genetically Engineered Antibodies  XII. Concluding Remarks  References  Maternally Transmitted Antigen  JOHN R. RODGERS, ROGER SMITH III, MARILYN M. HUSTON,  AND ROBERT R. RICH	
IV. Preparation of Donor Lymphocytes for Fusion  V. Cell Fusion  VI. Human-Murine Hybridomas  VII. Human + Human Hybridomas  VIII. Human × Human-Mouse Heterohybridomas  IX. Characterization of Human Monoclonal Antibodies  X. Propagation of Human-Mouse and Human-Human Hybridomas in Vivo  XI. Genetically Engineered Antibodies  XII. Concluding Remarks  References  Maternally Transmitted Antigen  JOHN R. RODGERS, ROGER SMITH III, MARILYN M. HUSTON,	

	CONTENTS	vii
III.	Maternal Inheritance of Mta Polymorphisms	318
IV.	Mta Shares Important Functional Properties with Class I Major	
	Histocompatibility Antigens	329
V.	Phylogenetic Considerations	337
VI.	Models of the Genetic Mechanism of Mta	338
	Generation of CTLs Specific for the Maternally Transmitted Antigen	348
	Conclusions	350
	References	352
_	cytosis of Particulate Activators of the Alternative Complement Pathway: of Fibronectin JOYCE K. CZOP	
I.	Introduction	361
	Phagocytosis of Unopsonized Zymosan by Human Monocytes	363
	Phagocytosis of Unopsonized Zymosan by Nonelicited Murine Macrophages	376
IV.	Phagocytosis of Nonmicrobial Particulate Activators by Human Monocytes Phagocytosis of Nonmicrobial Particulate Activators by Nonelicited Murine	380
••	Macrophages	383
VI	Particulate Activators of the Alternative Complement Pathway	384
	Effects of Fibronectin	386
	Conclusions	392
	References	394
INDEX	· · · · · · · · · · · · · · · · · · ·	399
	The Or Proper Volume	415

# The Antigen-Specific, Major Histocompatibility Complex-Restricted Receptor on T Cells

## PHILIPPA MARRACK AND JOHN KAPPLER

Department of Medicine, National Jewish Hospital and Research Center, and
Departments of Biophysics, Biochemistry and Genetics,

Departments of Microbiology,
and Department of Medicine,
University of Colorado Health Sciences Center,
Denver, Colorado

I.	Introduction	1
: II.	Identification and Properties of T Cell Receptor Proteins	3
III.	Properties of cDNA and Genomic Clones Encoding T Cell Receptor Proteins	5
		10
V.	Rearrangement and Expression of T Cell Receptor Genes in the Thymus	10
VI.	Expression of Receptor Genes and Proteins on Peripheral T Cells	Ì3
VII.	V Region Repertoire and Variability	15
VIII.	Chromosomal Mapping of T Cell Receptor Genes	16
IX.	Allelic Exclusion of T Cell Receptor Genes	
X.	Association of the Receptor and T3	18
XI.	Is the Receptor Responsible for Specific Binding to Both Antigen and MHC by	, · •
11		19
XII.	Interactions of T Cells with Their Targets	21
XIII.	Concluding Remarks	23
		24

### I. Introduction

The receptor on T cells responsible for clonal recognition of and response to antigen by these cells has been long sought, not only because of the insights an understanding of these molecules might shed on human health and disease, but also because of scientific curiosity about the way in which such molecules might function. Early attempts to isolate these proteins relied heavily on the idea that T cell receptors might be similar, if not identical, to immunoglobulin. In retrospect although this idea was not unreasonable, it certainly created a good deal of confusion in the field.

Thus, conflicting data were generated about the presence on T cells, or T cells' secretion, of proteins cross-reacting with anti-immunoglobulin anti-bodies (Marchalonis and Cone, 1973; Vitetta et al., 1973; Eichmann and Rajewsky, 1975; Binz and Wigzell, 1977; Ben Neriah et al., 1980). Similarly, attempts to pursue T cell receptors based on the assumption that, like anti-body molecules, they would bind free antigen molecules, also led to opposing results (Hunter et al., 1972; Feldmann, 1972; Binz and Wigzell, 1975;

Krawinkel et al., 1977). Meanwhile data accumulated which suggested that the receptors for antigen on most T cells might not be immunoglobulins.

Perhaps the first indications of this came from experiments which showed that T cells and B cells from the same animals did not recognize the same determinants on antigens. For example, many experiments showed that T cells do not distinguish between native and denatured antigens, whereas antibody commonly does (Parish, 1971; Mason et al., 1972; Schirrmacher and Wigzell, 1972; Chesnut et al., 1980). Moreover, T cells and B cells primed to a particular antigen frequently cross-react differently on related antigens (Hoffmann and Kappler, 1972; Playfair, 1972), although exceptions to this rule were also noted (Rajewsky and Mohr, 1974). In addition, the confusing phenomena of immune response (Ir) genes also had to be explained, since these major histocompatibility complex (MHC)-associated genes were known to affect T cell reactivity without much direct effect on B cells (Katz et al., 1973b; Press and McDevitt, 1977).

The explanation for these findings was founded on the work in the early 1970s of Kindred and Shreffler, Katz and his colleagues, and Shevach and Rosenthal (Kindred and Shreffler, 1972; Katz et al., 1973a,b; Rosenthal and Shevach, 1973; Shevach and Rosenthal, 1973). Later Zinkernagel and Doherty and others built on the findings of these groups, and demonstrated directly for the first time that cytotoxic T cells only kill antigen-bearing cells if the antigen is presented to them in association with products of the MHC on the surfaces of antigen presenting cells (Zinkernagel and Doherty, 1975; Shearer et al., 1975; Gordon et al., 1975; Bevan, 1975). Numerous workers have since confirmed this finding for T cells responsible for B cell help, delayed hypersensitivity, and lymphokine secretion (Kappler and Marrack, 1976, 1977; Singer et al., 1978; Sprent, 1978; Schwartz et al., 1978; Waldmann, 1978; von Boehmer and Haas, 1981).

The discovery that many T cells recognize antigen only in association with products of the MHC led to the conclusion that at least a component of the receptor on T cells was not immunoglobulin. This, coupled with numerous observations that many T cells do not secrete immunoglobulins (Roehm et al., 1984b) or usually have mRNA encoding these molecules (Kronenberg et al., 1980, 1983; Kurosawa et al., 1981), suggested that the isolation of T cell receptors might be most easily accomplished by methods which did not depend on the idea that these molecules were related to immunoglobulins.

In fact the two methods which were most successful in identifying receptors were both based on a minimum number of assumptions. The first experiments depended on the idea that receptors would bear antigenic determinants which would not necessarily cross-react between different T cell clones, and the second was based on the assumption that receptor mRNA would be transcribed only in T cells.

# II. Identification and Properties of T Cell Receptor Proteins

A number of investigators identified molecules of interest on T cells by injecting bulk, uncloned T cells or T cell tumors from one strain or species into other animals and studying the properties of the antisera and/or monoclonal antibodies so identified. By these means many important proteins on the surfaces of T cells were identified, some of which appeared to have a role in T cell recognition of antigen, because antibodies against them either blocked or stimulated T cell activation (Itakura et al., 1972; Cantor and Boyse, 1975; Shiku et al., 1976; Nakayama et al., 1979; Davingnon et al., 1981; Swain, 1981; Biddison et al., 1982; Reinherz et al., 1982). Since none of these molecules appeared to vary in amino acid sequence between one T cell clone and another, however, it was concluded that they did not contribute to specific recognition of antigen and MHC by T cells. These molecules are of great interest, however. Some of their properties are discussed in detail below.

A major advance occurred with the description by Infante et al. (1982) of antisera raised in mice against alloreactive T cell clones. These antisera stimulated division of the immunizing T cell clone and had no effect on other, closely related T cells, suggesting that the functional antibodies involved were recognizing some clone-specific determinant on the surface of the T cell clone used for immunization, a determinant which might be the analog for T cell receptors of an immunoglobulin idiotype. This work was followed by the description of other antisera with similar properties, and finally by reports from a number of laboratories of monoclonal antibodies which recognized clone-specific determinants bourne by the T cell clones, tumors, or hybridomas used for immunization (Allison et al., 1982; White et al., 1983; Meuer et al., 1983b; Haskins et al., 1983; Samelson and Schwartz, 1983; Kaye et al., 1983; Bigler et al., 1983; Lancki et al., 1983; Staerz et al., 1984; Kranz et al., 1984).

Many properties of these monoclonal antibodies indicated that they bound receptors on T cells. First, their specificity for particular T cell clones showed, of course, that the molecule bound had determinants that were unique to a particular clone. Of all T cell surface proteins, only the receptor for antigen and MHC would have this characteristic. Second, these antibodies inhibited the responses or binding to antigen plus MHC of target T cell clones (Haskins et al., 1983). Alternatively, under certain circumstances the antibodies stimulated responses of target T cells. This was particularly apparent if the antibodies were made polyvalent, by coupling to Sepharose beads for example (Kaye et al., 1983; Kappler et al., 1983b; Meuer et al., 1983c). Again, these are characteristics that would be expected of antibodies binding part of the T cell receptor. Third, we demonstrated that a mono-

clonal antibody, KJ1-26, raised against an ovalbumin-specific, IA<sup>d</sup>-restricted T cell hybridoma, DO-11.10, failed to bind to subclones of this hybridoma which had lost the ability to bind to or respond to ovalbumin plus IA<sup>d</sup>, again suggesting that the antibody concerned did indeed bind all or part of the receptor for ovalbumin plus IA<sup>d</sup> (Haskins et al., 1983). Fourth, this same clone-specific anti-receptor antibody, KJ1-26, was used to screen a large panel of independent T cell hybridomas prepared from T cells of BALB/c (H-2<sup>d</sup>) mice primed with ovalbumin. The antibody bound to a single hybridoma of about 400 tested, and this T cell hybridoma turned out to have the same rare fine specificities, both for antigen and MHC, as the T cell hybrid. DO-11.10, against which the antibody was raised. This result could only be compatible with the reaction of the antibody with the antigen- and MHC-specific receptor on the T cell (Marrack et al., 1983b).

Finally, all monoclonal antibodies so far described with properties of the type listed above precipitate similar surface molecules from target T cells. These molecules are disulfide-bonded heterodimeric glycoproteins with characteristics that are both reminiscent of yet distinguish them from

immunoglobulins.

Although like antibodies these molecules are constructed of two different kinds of polypeptide chains, each molecule contains a single chain of each type. The two polypeptide chains are of similar molecular weights, being both about 43,000 in mouse (Allison et al., 1982; Kappler et al., 1983b). In man the more acidic, \alpha, chain is between 45,000 and 50,000, and the more basic, B, chain is lower in molecular weight at about 40,000 (Meuer et al., 1983a; Kappler et al., 1983a). Both α and β chains are extensively glycosylated. In mouse both chains bear both N-linked and O-linked sugar residues. The polypeptide backbones, stripped by endoglycosidases or synthesized in the presence of tumicamycin, have been reported to be 31-32K (B chain). and 27-31K (α chain) (McIntyre and Allison, 1984; Kave and Janeway, 1984). The molecular weights of the amino acid sequences predicted from cDNA clones suggest the lower of these molecular weights for the \alpha chain is probably more accurate (Chien et al., 1984a; Saito et al., 1984a). The difference in molecular weights between human α and mouse β chains seems to be entirely due to more extensive glycosylation of the α chain in this. species (Oettgen et al., 1984). Probably because of different amino acid sequences in their variable regions, however, both chains vary in molecular weight and charge when isolated from different T cell clones (Kappler et al., 1983b). In addition, peptide fingerprinting showed that α chains from different clones had peptides which distinguished them, and also peptides which they shared. This was also true for B chains, indicating that both chains had immunoglobulin-like variable and constant regions. Finally, peptide fingerprinting showed that  $\alpha$  and  $\beta$  chains had no peptides in common, proving

that they were not derived from the same collection of genes (Acuto et al., 1983; Kappler et al., 1983a).

Apart from the disulfide bond between the two chains, data from experiments in which receptor polypeptides were reduced with limiting concentrations of 2-mercaptoethanol indicated that intrachain disulfide bonds also existed (Samelson and Schwartz, 1983). The interchain disulfide bond is the most sensitive to reduction (Samelson and Schwartz, 1983; J. Kappler, unpublished observations). Interestingly this parallels results with immunoglobulins in which the interheavy chain bonds are most easily destroyed by reducing agents.

Contrary to expectations the gross structural properties and peptide fingerprints of  $\alpha$  and/or  $\beta$  chains could not be used to distinguish receptors on T cells specific for class I MHC products from those on class II specific cells. Class I- and class II-restricted cells all shared the same <sup>125</sup>I surface labeled peptides after digestion with trypsin or pepsin (Acuto et al., 1983; Kappler et al., 1983a). The possibility remained, however, that some part of the receptor buried deeply in the membrane, or in the cell cytoplasm, which would be inaccessible to the <sup>125</sup>I-labeling methods used in these experiments, might be different in cells with these different specificities. This idea has not been supported by molecular biological analyses (see below).

In summary the receptor on T cells for antigen plus MHC has been isolated using monoclonal antibodies. The molecule is a disulfide-bonded heterodimer of 85–90K. The two glycopolypeptide subunits appear unrelated to each other and to immunoglobulin. Each has variable and constant peptides. The overall structure of the molecule is therefore similar in design to the antibody molecule.

# III. Properties of cDNA and Genomic Clones Encoding T Cell Receptor Proteins

Early in 1984 two groups reported the sequences of cDNA clones isolated from subtraction libraries of a human T cell leukemia (Yanagi et al., 1984) or of mouse T cell hybridomas (Hedrick et al., 1984a,b). The mRNAs which gave rise to these clones are expressed only in T cells, and the cDNA clones bind DNA which rearranges between the germ line and mature T cells. The amino acid sequences predicted by these clones are immunoglobulin-like, having two domains with properties very similar to those found in immunoglobulins, containing intrachain disulfide loops and other residues such as Trp-32, Gln-35, and Trp-178 at conserved positions. Each of these sequences also contains a leader sequence, a J-like region, a hinge-like portion concerning a cysteine residue, which is presumably involved in covalently linking the  $\alpha$  and  $\beta$  chains, a transmembrane region and a short cytoplasmic tail (diagrammed in Fig. 1). Sites for N-linked glycosylation are also present.




Fig. 1. Structure of mouse receptor and receptor-like polypeptides. The diagrams show to scale the predicted protein structures of mouse  $\alpha$ ,  $\beta$ , or  $\gamma$  polypeptides. The leader, variable plus D, J, constant domain, transmembrane, and cytoplasmic regions are indicated for each chain. Also shown are some of the cysteine residues, with their probable disulfide linkages. Sites for N-linked glycosylation (CHO) are shown for the constant regions only. Data are from Hedrick et al. (1984b), Saito et al. (1984a,b), and Chien et al. (1984a).

When the sequences of cDNA inserts isolated from different T cell hybridomas are compared it is clear that these genes are immunoglobulin-like in one other crucial respect since the predicted amino acid sequences of the first domain are clearly variable, whereas the second domain, hinge, transmembrane, and cytoplasmic region sequences appears (almost) constant. Extensive homology between the nucleotide and predicted amino acid sequences of the human and mouse cDNA clones shows that they code for the same chain of the T cell receptor. N terminal protein sequencing later showed that the chain encoded is that of the  $\beta$  chain (Acuto et al., 1984; Hannum et al., 1984a,b).

Many interesting conclusions have been drawn already from studies on these recently discovered  $\beta$  chain genes. First, the structure of these genes in the germ line has been analyzed (diagrammed in Fig. 2). The germ line structure of mouse and man is very similar. In each case there are two closely linked genes with very similar structures, exon sequences, and predicted amino acid sequences encoding two constant regions. Each constant region gene is constructed from four exons. The positions and lengths of the introns interrupting the two C region genes are almost identical. The exons




Fig. 2. Germ line structure of the mouse β chain locus. This is shown to scale without indication of the intron/exon structure of Cβ1 and Cβ2. Data are from Gascoigne et al. (1984), Malissen et al. (1984), Siu et al. (1984a,b), and Kavaler et al. (1984).

of each gene consist of one poding for the second, constant region, extracellular domain, a very small exon coding for the hinge-like region, one exon encoding the transmembrane region and finally an exon coding for the cytoplasmic tail and 3' untranslated region (Gascoigne et al., 1984; Malissen et al., 1984). Most interestingly in mouse the coding regions of the two constant region genes differ by only 24 of their 318 nucleotides, whereas the 3' untranslated regions of the two genes are different lengths, and also differ considerably in DNA sequence, being less than 50% homologous. The 24 base differences between the coding sequences for the two constant regions lead to only 4 amino acid changes, all in or near the transmembrane and cytoplasmic domains (Gascoigne et al., 1984). The fact that the 3' untranslated regions of these two genes are so dissimilar, coupled with the fact that the genomic organization of these genes in man is similar to that in mouse, suggests that duplication of the CB genes occurred before speciation of mouse and man. Gascoigne et al. (1984) have suggested a time about 120 million years ago. In that case, the conservation of nucleotide and coded amino acid sequences of the two constant regions is really remarkable, and implies strong, selective pressures on the sequences encoded, or perhaps very recent or very frequent gene conversions in the coding sequences. The idea that the amino acid sequence of these genes is strongly conserved by pressure for it to function in a particular way is supported by the fact that the translated amino acid sequences of human and mouse CB regions are also very similar, only 37 amino acids of 177 encoded by these four exons differ.

There is no evidence that one or other C region is selectively expressed by one type of T cell, since class I<sub>1</sub> and class II-restricted cells have been found expressing Cβ1, and likewise other cells of both specifities have been found expressing Cβ2 (Royer et al., 1984; Kronenberg et al., 1985; Hedrick et al., 1985). The genomic structures of the two constant regions are similar in other ways. Both genes are preceded by a cluster of 6–7 functional J region genes, and about 500–600 bases upstream from each of these a D region segment is located (Gascoigne et al., 1984; Malissen et al., 1984; Siu et al., 1984a, b; Kavaler et al., 1984; Clark et al., 1984). The approximate structure

of the entire locus is shown in Fig. 2. In functional T cells it has been shown that each D region can rearrange to any of the J regions in the adjacent cluster by a looping out-insertion mechanism. In addition D\$\beta\$1 can rearrange to any of the J region genes in the second cluster, again by looping out and, insertion. In immature and mature T cells V region genes also rearrange to either D and/or J cluster. There is evidence that in some cases rearrangements may occur by mechanisms such as sister chromatid exchange or inversion (Chien et al., 1984b; Siu et al., 1984a,b; Kronenberg et al., 1985; Born et al., 1985).

In any case the mechanisms of rearrangement for these genes seem to be very similar to those used for immunoglobulin gene rearrangement in B cells. Thus D segments and the 5' sides of I regions are flanked by hentamer/nonamer sequences similar to those which are used to indicate rearrangement sites for heavy and light chains (Siu et al., 1984b; Kavaler et al., 1984; Sakano et al., 1979; Early et al., 1980; Sakano et al., 1980; Tonegawa, 1983). One difference was noted, however, in that if the rules worked out for immunoglobulin genes apply here, there is evidence that VB genes may have the option of rearranging directly to a I region gene. Thus D region genes are flanked by heptamer/nonamer sequences with spacers of 12 nucleotides on their 5' sides, and 23 nucleotides on their 3' sides. The heptamer/nonamer sequences of I region genes all have 12 base spacers on their 5' sides. This implies that a V region gene with 3' heptamer/nonamer sequences having a 23 base spacer could rearrange either to D or I (Siu et al.. 1984b: Kavaler et al., 1984). Indeed there is some evidence from the sequencing of a B chain of a cDNA clone from the human T cell leukemia HPB-MLT that D region genes may sometimes be missing, though of course such sequences may theoretically be so small as to be invisible (Jones et al., 1985).

Again as in the case of immunoglobulins there is evidence that non-germ line encoded nucleotides can be introduced at the point of V to D or D to J joining, leading to so-called N region diversity (Siu et al., 1984b; Sakano et al., 1981; Alt and Baltimore, 1982). All in all, it is clear that  $\beta$  chains use many of the strategies previously described for immunoglobulin genes to achieve diversity. This will be discussed at greater length below.

cDNA clones encoding  $\alpha$  chain polypeptides have been isolated, like  $\beta$  chain cDNAs, from T cell-specific cDNA subtraction libraries (Chien et al., 1984a; Saito et al., 1984b) and also by the use of amino acid sequences of tryptic peptides from the  $\alpha$  chain of the human leukemia, HPB-MLT (Sim et al., 1984). In this latter case degenerate oligonucleotide probes were built to match the known amino acid sequences, and were used to isolate cDNA clones which encoded the  $\alpha$  chains in question. Like  $\beta$  chains, both in mouse and man,  $\alpha$  cDNA probes bind to mRNA expressed only in T cells and detect

genomic DNA which rearranges between the germ line and mature T cells. Again, there is extensive homology between the coding DNA sequences and translated amino acid sequences of mouse and man, though this is less marked than for  $\beta$  chains.

As for B chains, the amino acid sequences known or predicted for a chains suggest a strong relationship to the immunoglobulin family (Fig. 1), a chain polypeptides each have a leader sequence of about 20 amino acids, two immunoglobulin-like domains defined by intrachain disulfide bonds and other conserved residues, a I-like sequence, and hinge, transmembrane. and cytoplasmic regions (Chien et al.: 1984a: Saito et al., 1984b: Sim et al. 1984). There is evidence that D region sequences are optional, as for B chains (Sim et al., 1984). The first immunoglobulin like domain varies in sequence from clone to clone as expected for a V region. The second, C region domain is somewhat surprising since it is unexpectedly short, the disulfide-bonded intrachain loop includes only 50 rather than the usual 70 amino acids, and lacks residues that are otherwise universally conserved in the immunoglobulin family such as Tro-148. On the other hand, the socalled hinge region, containing a cysteine residue presumably involved in cross-linking to the B chain, is more reminiscent of an immunoglobulin hinge than its counterpart in the 8 chain.

The supposed transmembrane region of human and mouse  $\alpha$  chains contains 2 positively charged amino acids. This was surprising, since  $\beta$  chain transmembrane regions had previously been shown to contain one basic amino acid, and it had been suggested that  $\alpha$   $\beta$  dimers might be stabilized in the membrane by the presence of a complementary negatively charged amino acid in the  $\alpha$  chain transmembrane region. The significance of the fact that the two chains possess jointly 3 basic amino acids in what is thought to be that portion of their sequences which spans the lipid bilayer of the cell will be discussed in greater detail below.

So far very little of the germ line structure of  $\alpha$  chain genes has been reported. It is already clear, however, that, unlike C $\beta$ , the locus contains only one functional C region gene, and there must be a very large intron between the J $\alpha$ s and C $\alpha$ s since no restriction enzyme used by us has shown rearrangements involving J $\alpha$  on Southern blots using a C $\alpha$  probe (J. Yagüe and W. Born, personal communication).

In summary cDNA clones encoding the  $\alpha$  and  $\beta$  chains of the T cell receptor have now been isolated. They demonstrate that these genes are expressed exclusively in T cells and have properties very similar to those of immunoglobulins. The functional gene is composed of rearranged V, (D), and J segments and a constant region portion. The mechanisms causing rearrangement seem to be similar to those used by immunoglobulin genes in B cells.